Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access protocol of oral Farydak (panobinostat) plus bortezomib and dexamethasone in relapsed and relapsed/refractory multiple myeloma
2014-003239-21Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of panobinostat in multiple myeloma (MM), sponsored by Novartis. Primary endpoints: Safety - adverse events, Safety - Grade 3 and 4 adverse events and 4 more. Started Oct 2014; status: completed.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2014-003239-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003239-21.